Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: Bintrafusp alfa
Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany